Search results
Results from the WOW.Com Content Network
The ACTH test (also called the cosyntropin, tetracosactide, or Synacthen test) is a medical test usually requested and interpreted by endocrinologists to assess the functioning of the adrenal glands' stress response by measuring the adrenal response to adrenocorticotropic hormone (ACTH; corticotropin) or another corticotropic agent such as tetracosactide (cosyntropin, tetracosactrin; Synacthen ...
Low-dose and high-dose variations of the test exist. [4] The test is given at low (usually 1–2 mg) and high (8 mg) doses of dexamethasone, and the levels of cortisol are measured to obtain the results. [5] A low dose of dexamethasone suppresses cortisol in individuals with no pathology in endogenous cortisol production.
ACTH stimulation test: ACTH: cortisol, 17α-hydroxyprogesterone: adrenal insufficiency, Congenital adrenal hyperplasia (21-hydroxylase, 3 beta) metyrapone panel
A low-dose ACTH stimulation test has been suggested as a sensitive test for secondary adrenal insufficiency diagnosis. [10] When compared to insulin tolerance testing [11] and the high-dose ACTH test, this test allows for a more accurate identification of patients with secondary adrenal insufficiency. [12]
An ACTH stimulation test involving administration of corticotropin-releasing hormone (CRH) or another agent can differentiate this condition from ectopic ACTH secretion. In a patient with Cushing's disease, the tumor cells will be stimulated to release corticotropin and elevated plasma corticotropin levels will be detected. [ 8 ]
by increased plasma angiotensin II, ACTH, or potassium levels. The ACTH stimulation test is sometimes used to stimulate the production of aldosterone along with cortisol to determine if primary or secondary adrenal insufficiency is present. by plasma acidosis. by the stretch receptors located in the atria of the heart.
The corticorelin stimulation test helps to differentiate between the causes for adrenocorticotropic hormone (ACTH)-dependent hypercortisolism.It is used to distinguish a pituitary source of excessive ACTH secretion from a different source.
It is possible to test for heterozygosity by measuring 17OHP elevation after ACTH stimulation. [139] More than 200 disease-causing variants within the CYP21A2 gene have been identified so far that lead to 21-hydroxylase deficiency. [140] Most patients have at least two of these variants present as compound heterozygous. [141] [142] [143]